Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Science Officer | February 27, 2019 | March 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date February 27, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 152,408 |
Reported balance
After 2019-02-27 transaction · row 1
1 source rowRow 1 · 2019-02-27 · Exercise / conversion · Acquired 6,945 · Balance 152,408 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 13,888 |
Reported balance
After 2019-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-27 · Exercise / conversion · Disposed 6,945 · Balance 13,888 F1: Fully vested as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2017 Filed Jun 13, 2017 18:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 15,000 | $15.02 | $225,225.00 |
DisclosureSEC source: 0001209191-17-039655 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,083 F1 · price: On June 9, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 15,000 shares in multiple trades at prices ranging from $15.00 to $15.10. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 109,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005227 · doc4.xml · derivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,200 Underlying: Ordinary Shares · 109,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Kirson's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Kirson's continued employment through such dates. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 273,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0000899243-17-005227 · doc4.xml · derivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,000 Underlying: Ordinary Shares · 273,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: Options to buy 273,000 ordinary shares will vest and become exercisable in equal installments on each of February 22, 2018, 2019, 2020 and 2021, subject to Mr. Kirson's continued employment through such dates. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to buy Ordinary Shares · Derivative | 156,073 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0000899243-16-034974 · doc4.xml · derivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 156,073 shares Expires 2016-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 156,073 | $0.17 | $26,532.41 |
DisclosureSEC source: 0000899243-16-034974 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.